- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
- Interventions
- Bimekizumab
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 64
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Bimekizumab
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Roseville, California • Sacramento, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- AviClear
- Device
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Spesolimab, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Fountain Valley, California • Los Angeles, California • Sacramento, California + 1 more
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- SPY072, Placebo, bimekizumab
- Drug
- Lead sponsor
- Spyre Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 12
- States / cities
- Irvine, California • Indianapolis, Indiana • Bowling Green, Kentucky + 9 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Brensocatib, Placebo
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Sacramento, California • Coral Gables, Florida + 22 more
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- NAV-240, Placebo to match NAV-240
- Drug
- Lead sponsor
- Navigator Medicines, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Maitland, Florida + 9 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Bioelectric Dressing, Standard Gauze Dressing
- Device · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 15
- States / cities
- San Diego, California • Whittier, California • Coral Gables, Florida + 11 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Mediterranean Diet Counseling, Mediterranean Food Support
- Behavioral · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Hidradenitis Suppurativa
- Interventions
- PTM-001, Placebo
- Drug
- Lead sponsor
- Phoenicis Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Redwood City, California • Worcester, Massachusetts • Cincinnati, Ohio
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- povorcitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 67 more
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Radiated axilla
- Radiation
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Cherry Hill, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Hidradenitis Suppurativa
- Interventions
- RIST4721, Placebo
- Drug
- Lead sponsor
- Aristea Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 7 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Bimekizumab, Adalimumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Coral Gables, Florida • Orange, Florida + 8 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Gentian Violet
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 64 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- EVO101
- Drug
- Lead sponsor
- Virginia Clinical Research, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Deucravacitinib, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
- Interventions
- KT-474/Placebo, KT-474
- Drug
- Lead sponsor
- Kymera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Povorcitinib, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Arkansas City, Arkansas • Fort Smith, Arkansas + 32 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Bimekizumab
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 658 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- antibiofilm surfactant wound gel (ABWG)
- Device
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida